Release Date: March 31, 2025
Expiration Date: March 31, 2026
Activity Overview
This online, on-demand virtual symposium brings together renowned experts in limited-stage small cell lung cancer (LS-SCLC). In this educational program, these experts discuss the latest developments reshaping the treatment landscape for LS-SCLC. Among the topics of discussion are practical considerations and impact of immunotherapy and combination approaches in LS-SCLC, challenges in SCLC treatment, and future research and clinical interventions aimed to meet the needs of patients in real-world settings
This educational activity is an archive of the live symposium held on February 20, 2025.
Target Audience
This educational activity is directed toward medical oncologists, radiation oncologists, pathologists, molecular pathologists, thoracic surgeons, and pharmacists.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate current standards of care for LS-SCLC, including the role of concurrent CRT and the integration of evidence-based therapeutic strategies.
- Interpret emerging clinical trial data to assess the potential impact of immunotherapy and combination approaches in LS-SCLC management.
- Discuss the practical application of immunotherapy in LS-SCLC, including patient selection, timing, duration, and strategies to monitor and manage treatment-related toxicities.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.
Physicians’ Education Resource®, LLC (PER®) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. PER has approved this application-based activity for 1.00 ACPE CE hours. The Universal Activity Number for this activity is 0661-0000-25-003-H01-P. Eligibility for credits requires full attendance, and submission of activity evaluation, NABP e-pid# and month/date of birth within 45 days of activity completion. Please allow up to 60 days for credit processing. No partial credits are given. This UAN expires June 30, 2026.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here